Genor Biopharma Co. Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Genor Biopharma Co. Ltd.
Novartis’s Kisqali Strikes Gold In Adjuvant Early Breast Cancer Setting
The Swiss major’s CDK4/6 inhibitor has met the primary endpoint in a pivotal breast cancer trial earlier than expected, with success in the intermediate risk group representing a $4bn opportunity untapped by rival Eli Lilly.
BeiGene Latest Chinese Biotech To Double Down On mRNA For Cancer
Chinese biotechs have reached deals for cancer therapies to explore the novel uses of messenger RNA technology beyond COVID-19 vaccines, as the mRNA COVID-19 vaccine fame starts fading.
China Rings In New Year With Major Deals, Record IPOs And Trends To Watch
From bringing innovative new drugs to global markets, to record-setting fundraisings and initial public offerings, five trends are emerging in China's health sector that are worth closely watching in 2021.
Finance Watch: Kronos Bio IPO Raises $250m To Fund Novel Cancer Drugs
Initial public offerings by Norbert Bischofberger’s start-up as well as Spruce Biosciences and Shattuck Labs bring the US total to 64 in 2020. Also, the pipeline of health care SPACs is growing, Everest and Genor went public in Hong Kong, Idorsia leads recent follow-on offerings and Corbus cuts jobs.
- Large Molecule
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.